593 related articles for article (PubMed ID: 20491613)
1. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
[TBL] [Abstract][Full Text] [Related]
2. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
[TBL] [Abstract][Full Text] [Related]
3. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
4. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
6. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
7. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
Wolfenstetter SB
Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
[TBL] [Abstract][Full Text] [Related]
8. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
10. The burden of diabetes mellitus for medicare beneficiaries.
Costantino ME; Stacy JN; Song F; Xu Y; Bouchard JR
Popul Health Manag; 2014 Oct; 17(5):272-8. PubMed ID: 24865764
[TBL] [Abstract][Full Text] [Related]
11. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study.
Johnson JA; Pohar SL; Majumdar SR
Diabetes Care; 2006 Nov; 29(11):2403-8. PubMed ID: 17065675
[TBL] [Abstract][Full Text] [Related]
12. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
[TBL] [Abstract][Full Text] [Related]
13. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
14. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
17. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
18. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
19. The economic effect of hypoglycemia in a health plan.
Heaton A; Martin S; Brelje T
Manag Care Interface; 2003 Jul; 16(7):23-7. PubMed ID: 12908214
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
